Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

After learning of the warning letter, an investor accused Applied of knowing about these trial issues but not disclosing them ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

After less than a year on the job, the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., is leaving her post at ...

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in ...